PharmaShots | Incisive News in 3 Shots

Subscribe Now

P-IIB

Horizon Reports First Patient Enrollment in P-IIb Trial of HZN-825 for the Treatment of Diffuse Cutaneous Systemic Sclerosis

Horizon Reports First Patient Enrollment in P-IIb Trial of HZN-825 for the Treatment of Diffuse Cutaneous Systemic Sclerosis

November 11, 2021

Johnson & Johnson Discontinues the P-IIb Imbokodo Trial of HIV Vaccine Regimen for HIV Infection

Johnson & Johnson Discontinues the P-IIb Imbokodo Trial of HIV Vaccine Regimen for HIV Infection

September 1, 2021

Theravance Reports Results of Izencitinib in P-IIb Dose-Finding Induction Study for the Treatment of Ulcerative Colitis

Theravance Reports Results of Izencitinib in P-IIb Dose-Finding Induction Study for the Treatment of Ulcerative Colitis

August 24, 2021

$Bayer Reports Results of Eliapixant (BAY1817080) in P-IIb Study for the Treatment of Refractory Chronic Cough$

Bayer Reports Results of Eliapixant (BAY1817080) in P-IIb Study for the Treatment of Refractory Chronic Cough

August 4, 2021

Santhera and ReveraGen Report Results of Vamorolone in P-IIb VISION-DMD Study for Duchenne Muscular Dystrophy

Santhera and ReveraGen Report Results of Vamorolone in P-IIb VISION-DMD Study for Duchenne Muscular Dystrophy

June 1, 2021

AgeneBio Reports Completion of Patient Enrollment in P-IIB HOPE4MCI Trial for AGB101 to Treat Amnestic Mild Cognitive Impairment due to Alzheimer Disease

AgeneBio Reports Completion of Patient Enrollment in P-IIB HOPE4MCI Trial for AGB101 to Treat Amnestic Mild Cognitive Impairment d...

April 22, 2021

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us